A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

This is the first study to administer ziftomenib to Japanese patients. In this study, the efficacy, safety, and pharmacokinetics of ziftomenib will be evaluated in patients with relapsed or refractory NPM1-mutated acute myeloid leukemia

Trial Details

NCT ID
NCT07623616
Phase
PHASE2
Sponsor
Kyowa Kirin Co., Ltd.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • ziftomenib
Locations (sample)
  • Chiba, Japan|35.6,140.11667
  • Gifu, Japan|35.42291,136.76039
  • Hyōgo, Japan|43.36667,144.43333
  • Ibaraki, Japan|34.81641,135.56828
  • Kagoshima, Japan|31.56667,130.55

Key Eligibility Criteria

  • Voluntary written informed consent and willingness to comply with all study procedures
  • Age ≥ 18 years
  • Confirmed diagnosis of acute myeloid leukemia (AML)
  • Patients with R/R AML with NPM1-m

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →